Louis Lacombe
Chercheur universitaire clinicien
Axe Oncologie
Métastases et progression du cancer
Mécanismes de la carcinogenèse
Urologie
Oncologie clinique
Publications
View all-
article Leong DP, Higano C, Cano Garcia C, Fradet V, Siemens DR, Niazi T, Shayegan B, Guha A, Cirne F, Selvanayagam JB, Violette PD, Valle FH, Lavallée LT, Duceppe E, Anderson P, Xavier D, Lopez-Lopez JP, Villareal Trujillo N, Galapo Kann A, Piccoli RK, Mourtzakis M, Sarid D, Narasimha S, Luke PPW, Hajjar LA, Lukka H, Klotz L, Balasubramanian K, Mian R, Agapay S, Rangarajan S, Karampatos S, Ng KKH, Avezum A, Devereaux PJ, Pinthus JH and
Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial
JAMA Intern Med 2026.
-
article Cano Garcia C, Pinthus J, Avezum A, Devereaux PJ, Klotz L, Higano C, Fradet V, Selvanayagam J, Guha A, Hajjar L, Lopez-Lopez JP, Xavier D, Ng K, Rangarajan S, Karampatos S, Agapay S, Mian R, Balasubramanian K, Cirne F, Huynh M, Davis MK, Hamilton RJ, Gopaul D, Mukherjee SD, Farooqi M, Benz AP, Richard R, Koo CYC, Leong DP and
Identifying Patients With Prostate Cancer Who Benefit Most From Routine Cardiovascular Specialist Referral
JACC CardioOncol 2026.
-
article Choueiri TK, Motzer RJ, Karam JA, Yip W, Suárez C, Ye D, He Z, Caglevic C, Ferguson T, Chang YH, Rojas C, Iacovelli R and Ürün Y, Verzoni E, Vázquez Limón JC, Porta C, Uzzo RG, Lee JL, Venugopal B, McKay RR, Hammers H, Miyake H, Chahoud J, Liu H, Burgents JE, Sharma M, Powles TB and
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
N Engl J Med 395 (1), 2026.
Projects
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
- Aberrant UGT2B28 androgen inactivation pathway predict prostate cancer progression., from 2022-02-05 to 2027-03-31
- Biobangue UR0-1, from 2025-03-01 to 2029-03-30
- Metabolomics and lipidomics of prostate cancer progression: Leveraging the PROCURE, from 2025-03-01 to 2027-03-30
- Étude sur le role de la voie des glycosyltransferase CUGT) en cancer de la vessie, from 2025-03-01 to 2030-03-30
- Non-invasive biomarkers and patient-reported outcomes for precision oncology in Prostate Cancer, from 2026-06-01 to 2029-05-31
- Caractérisation hormonale et métabolique de l'évolution du cancer de la prostate dans la cohorte IRONMAN, from 2026-04-01 to 2029-04-01
- UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, from 2023-09-01 to 2025-08-31
- Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial , from 2024-06-17 to 2025-06-16
- Metabolomics and lipidomics of prostate cancer progression: Leveraging the PROCURE Biobank, from 2024-07-10 to 2025-03-31